Stock listing
OTC:GNNSF GenScript Biotech Corporation Stock
US listing (OTC) of GenScript Biotech Corporation · home listing HKEX:1548
Follow GenScript Biotech Corporation into a list and get an email when it puts out news.
Share price · OTC:GNNSF
$3.53 USD -0.25 (-6.6%)
Close on Nov 20, 2026
- Day range
- $3.53 – $3.53 USDNov 20, 2026
- Volume
- 241 sharesNov 20, 2026
- Market cap
- $8.05B USDAt the close on Nov 20, 2026 · price × 2.28B shares outstanding
- 52-week range
- $1.30 – $6.55 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5,595 USDMedian day 100 shares · 25 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:1548 · Home | $27.76 HKD | -3.08 (-10.0%) | 39,731,486 | $29.00 | $29.00 | $27.32 | $30.84 | Close on Nov 20, 2026 |
| OTC:GNNSF | $3.53 USD | -0.25 (-6.6%) | 241 | $3.526 | $3.53 | $3.526 | $3.78 | Close on Nov 20, 2026 |
| Frankfurt:G51 | €3.24 EUR | -0.16 (-4.7%) | — | €3.16 | €3.24 | €3.16 | €3.40 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · OTC:GNNSF · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.50 | 0.00 | 0.0% | $4.50 | $4.50 | $4.50 | 0 | |
| $4.50 | 0.00 | 0.0% | $4.50 | $4.50 | $4.50 | 0 | |
| $4.50 | 0.00 | 0.0% | $4.50 | $4.50 | $4.50 | 0 | |
| $4.50 | 0.00 | 0.0% | $4.50 | $4.50 | $4.50 | 0 | |
| $4.50 | 0.00 | 0.0% | $4.50 | $4.50 | $4.50 | 250 | |
| $4.50 | 0.00 | 0.0% | $4.50 | $4.50 | $4.50 | 0 | |
| $4.50 | 0.00 | 0.0% | $4.50 | $4.50 | $4.50 | 0 | |
| $4.50 | +0.25 | +5.9% | $4.38 | $4.50 | $4.38 | 500 | |
| $4.25 | 0.00 | 0.0% | $4.25 | $4.25 | $4.25 | 0 | |
| $4.25 | 0.00 | 0.0% | $4.25 | $4.25 | $4.25 | 0 | |
| $4.25 | +0.075 | +1.8% | $4.25 | $4.25 | $4.25 | 250 | |
| $4.175 | 0.00 | 0.0% | $4.175 | $4.175 | $4.175 | 0 | |
| $4.175 | 0.00 | 0.0% | $4.175 | $4.175 | $4.175 | 0 | |
| $4.175 | 0.00 | 0.0% | $4.175 | $4.175 | $4.175 | 0 | |
| $4.175 | 0.00 | 0.0% | $4.175 | $4.175 | $4.175 | 0 | |
| $4.175 | +0.125 | +3.1% | $4.182 | $4.182 | $4.175 | 900 | |
| $4.05 | -0.48 | -10.6% | $4.05 | $4.05 | $4.05 | 175 | |
| $4.53 | 0.00 | 0.0% | $4.53 | $4.53 | $4.53 | 320 | |
| $4.53 | -0.97 | -17.6% | $4.55 | $4.55 | $4.40 | 5,325 | |
| $5.50 | +0.30 | +5.8% | $5.50 | $5.50 | $5.50 | 153 | |
| $5.20 | -0.058 | -1.1% | $5.27 | $5.275 | $5.20 | 1,238 | |
| $5.258 | -0.542 | -9.4% | $5.258 | $5.258 | $5.258 | 100 | |
| $5.80 | -0.55 | -8.7% | $5.50 | $5.80 | $5.50 | 1,690 | |
| $6.35 | +0.55 | +9.5% | $6.55 | $6.55 | $6.35 | 1,630 | |
| $5.80 | +0.28 | +5.1% | $5.84 | $6.00 | $5.70 | 5,680 | |
| $5.52 | -0.18 | -3.2% | $5.52 | $5.52 | $5.52 | 1,000 | |
| $5.70 | +0.175 | +3.2% | $5.70 | $5.70 | $5.70 | 1,000 | |
| $5.525 | +0.175 | +3.3% | $5.525 | $5.525 | $5.525 | 500 | |
| $5.35 | 0.00 | 0.0% | $5.35 | $5.35 | $5.35 | 0 | |
| $5.35 | +0.30 | +5.9% | $5.35 | $5.35 | $5.35 | 500 | |
| $5.05 | 0.00 | 0.0% | $5.05 | $5.05 | $5.05 | 0 | |
| $5.05 | -0.60 | -10.6% | $5.05 | $5.05 | $5.05 | 363 | |
| $5.65 | 0.00 | 0.0% | $5.65 | $5.65 | $5.65 | 0 | |
| $5.65 | 0.00 | 0.0% | $5.65 | $5.65 | $5.65 | 0 | |
| $5.65 | +0.833 | +17.3% | $5.30 | $5.65 | $5.30 | 8,595 | |
| $4.817 | +0.717 | +17.5% | $5.09 | $5.09 | $4.817 | 1,020 | |
| $4.10 | 0.00 | 0.0% | $4.10 | $4.10 | $4.10 | 0 | |
| $4.10 | 0.00 | 0.0% | $4.10 | $4.10 | $4.10 | 0 | |
| $4.10 | 0.00 | 0.0% | $4.10 | $4.10 | $4.10 | 0 | |
| $4.10 | 0.00 | 0.0% | $4.10 | $4.10 | $4.10 | 0 | |
| $4.10 | 0.00 | 0.0% | $4.10 | $4.10 | $4.10 | 0 | |
| $4.10 | +0.10 | +2.5% | $4.10 | $4.10 | $4.10 | 100 | |
| $4.00 | 0.00 | 0.0% | $4.00 | $4.00 | $4.00 | 0 | |
| $4.00 | 0.00 | 0.0% | $4.00 | $4.00 | $4.00 | 0 | |
| $4.00 | -0.30 | -7.0% | $4.00 | $4.00 | $4.00 | 100 | |
| $4.30 | -0.35 | -7.5% | $4.30 | $4.30 | $4.30 | 100 | |
| $4.65 | 0.00 | 0.0% | $4.65 | $4.65 | $4.65 | 0 | |
| $4.65 | +0.25 | +5.7% | $4.60 | $4.65 | $4.515 | 1,660 | |
| $4.40 | -0.10 | -2.2% | $4.55 | $4.60 | $4.35 | 2,697 | |
| $4.50 | 0.00 | 0.0% | $4.50 | $4.50 | $4.50 | 460 | |
| $4.50 | +0.35 | +8.4% | $5.00 | $5.00 | $4.45 | 10,023 | |
| $4.15 | -0.45 | -9.8% | $4.15 | $4.15 | $4.15 | 1,000 | |
| $4.60 | +0.60 | +15.0% | $4.15 | $4.60 | $4.15 | 5,100 | |
| $4.00 | +0.14 | +3.6% | $3.90 | $4.00 | $3.90 | 6,806 | |
| $3.86 | 0.00 | 0.0% | $3.86 | $3.86 | $3.86 | 0 | |
| $3.86 | +0.16 | +4.3% | $3.80 | $3.86 | $3.80 | 6,000 |
- Ticker
- OTC:GNNSF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Voluntary announcement: financial results for the third quarter ended 30 September 2026 of a listed associate - legend biotech corporation
Latest earnings call · Aug 16, 2026
GenScript Biotech (HKEX:1548) Q2 2026 Earnings Call
Replay and transcript
Latest news
Voluntary announcement: legend announces presentations at the american society of hematology annual meeting
Nov 4, 2026
Closed $4.50 (0.0%) on Nov 5, 2026
Voluntary announcement: unusual price movement
Nov 3, 2026
Closed $4.50 (0.0%) on Nov 3, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 3, 2026
Closed $4.50 (0.0%) on Nov 3, 2026
Passing away of company secretary and process agent
Nov 2, 2026
Closed $4.50 (0.0%) on Nov 2, 2026
Voluntary announcement: legend announces preliminary sales for CARVYKTI for the quarter ended 30 September 2026
Oct 13, 2026
Closed $4.53 (-17.6%) on Oct 13, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Oct 6, 2026
Closed $6.35 (+9.5%) on Oct 6, 2026
Change in board lot size
Sep 21, 2026
Closed $5.65 (+17.3%) on Sep 21, 2026
Announcement pursuant to rule 13.10 of the listing rules
Sep 17, 2026
Closed $4.10 (0.0%) on Sep 17, 2026
List of directors and their role and function
Sep 16, 2026
Closed $4.10 (0.0%) on Sep 16, 2026
GenScript Biotech Corporation on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 21 in the last 12 months · 28 in all · newest Nov 10, 2026 · oldest 2025
- Calls
- 1 call with a replay · 1 with a transcript · latest Aug 16, 2026
- Decks
- 4 decks · latest August 2025
Where GenScript Biotech Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:1548 金斯瑞生物科技 · Home listing | HKEX | Hong Kong | HKD |
| gettex:G51 | gettex | Germany | EUR |
| OTC:GNNSF · This page | OTC | United States | USD |
| LS Exchange:A2ACSB | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2ACSB | Lang & Schwarz | Germany | EUR |
| Tradegate:G51 | Tradegate | Germany | EUR |
| Frankfurt:G51 | Frankfurt | Germany | EUR |
| Stuttgart:G51 | Stuttgart | Germany | EUR |
| Dusseldorf:G51 | Dusseldorf | Germany | EUR |
| Munich:G51 | Munich | Germany | EUR |
Valuation
EV/sales 7.8× against a median of 5.6×: 7th lowest of 11 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $58.79B HKD
- P/E
- Loss
- EV/sales
- 7.8×
- EV/EBITDA
- 22.8×
- Price/book
- 2.1×
- Gross margin
- 57.6%
- Operating margin
- 26.6%
- Net margin
- −55.5%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| GenScript Biotech Corporation · HKEX:1548 | US$8.08B | US$7.50B | n/a | 7.8× | 22.8× | 2.1× | −55.5% | 0.1× | n/a |
| Avantor, Inc. · NYSE:AVTR | US$10.06B | US$13.28B | 29.8× | 2.0× | 14.7× | 1.7× | 5.1% | 0.6× | 0.78 |
| WuXi XDC Cayman, Inc. · HKEX:2268 | US$9.64B | US$8.87B | 43.5× | 10.0× | 33.5× | 5.7× | 24.9% | 0.1× | n/a |
| Tempus AI, Inc. · NASDAQ:TEM | US$9.58B | US$8.99B | n/a | 6.0× | n/a | 19.1× | −12.5% | 0.0× | 2.51 |
| Bruker Corporation · NASDAQ:BRKR | US$8.62B | US$10.22B | n/a | 2.9× | 64.4× | 3.7× | −3.5% | 0.7× | 1.72 |
| Pharmaron Beijing Co., Ltd. Class A · SZSE:300759 | US$8.52B | US$8.23B | 32.1× | 3.4× | n/a | 3.4× | 11.1% | 0.1× | n/a |
| Bio-Rad Laboratories, Inc. · NYSE:BIO | US$7.84B | US$7.38B | 7.7× | 2.8× | 71.0× | 1.0× | 39.5% | 0.2× | 0.72 |
| Shenzhen New Industries Biomedical Engineering Co. Ltd. Class A · SZSE:300832 | US$7.51B | US$7.10B | 27.8× | 9.8× | n/a | 5.3× | 37.2% | 0.0× | n/a |
| Twist Bioscience Corporation · NASDAQ:TWST | US$7.04B | US$6.46B | n/a | 14.1× | n/a | 7.9× | −28.3% | 0.0× | 2.77 |
| Asymchem Laboratories (Tianjin) Co., Ltd. Class A · SZSE:002821 | US$6.83B | US$5.89B | 38.5× | 5.3× | n/a | 2.6× | 15.9% | 0.0× | n/a |
| Bachem Holding AG Class B · SIX:BANB | US$6.80B | US$6.99B | 38.4× | 8.4× | 29.7× | 4.0× | 21.4% | 0.1× | n/a |
| Median of the others | US$8.18B | US$7.80B | 32.1× | 5.6× | 33.5× | 3.9× | 13.5% | 0.1× | 1.72 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 45.43 HKD · Analysts' mean
- EPS, year to Dec 2026
- 0.030 · 1 analyst
- Revenue, year to Dec 2026
- 898.1M · 6 analysts
Team and board
| Officer | Role |
|---|---|
| Allen Guo | CEO of ProBio |
| Sherry Shao | Rotating CEO (on duty) of GenScript BioTech Corp. |
| Phil Zhou | Chief Financial Officer of GenScript BioTech Corp. |
| Ray Chen | President of GenScript Life Science Group |
| Kening Li | General Counsel and Chief Compliance Officer |
| Aylin Kosova Bilgin | Chief Marketing & Corporate Communications Officer |
| Kate Grusich | Senior Corporate Communications Manager |
| Aixi Bai | General Manager of Bestzyme |
| Bhama Parimoo | Head of Global DEI |
| Martin Rexroad | General Manager of US Site for GenScript |
Events
- Next results
- Mar 15, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| GenScript Biotech (HKEX:1548) Q2 2026 Earnings Call | Sun, Aug 16, 2026 · 7:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Aug 16, 2025 · Before open | +2.5% |
| Q2 2024 | Aug 29, 2024 | −0.2% |
| Q4 2021 | Mar 21, 2022 | +5.7% |
| Q4 2020 | Mar 26, 2021 | −4.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2025 Earnings Presentation | Earnings | 24 slides | August 2025 |
| 42nd Annual J.P. Morgan Healthcare Conference (January 2024) | Conference | 33 slides | Jan 10, 2024 |
| FY2022 Earnings Presentation | Earnings | 25 slides | 2023 |
| Investor Presentation (2018) | Investor deck | 46 slides | 2018 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 959.5M | 594.5M | 560.5M | 625.7M | 511.1M | 390.8M | 273.4M | 231.0M | 152.6M | 114.7M |
| Cost of revenue | 406.3M | 322.4M | 289.9M | 321.6M | 207.6M | 135.0M | 93.1M | 72.5M | 48.1M | 38.5M |
| Gross profit | 553.2M | 272.1M | 270.6M | 304.1M | 303.5M | 255.9M | 180.3M | 158.5M | 104.6M | 76.2M |
| Research and development | 71.2M | 53.8M | 52.7M | 390.1M | 358.4M | 263.4M | 186.0M | 74.1M | 18.1M | 9.47M |
| Selling, general and administrative | 128.6M | 114.4M | 106.8M | 182.5M | 302.5M | 90.3M | 55.3M | 40.6M | 22.0M | 30.4M |
| Operating income | 255.2M | 9.28M | 26.2M | -438.1M | -494.0M | -204.5M | -131.3M | 5.11M | 39.6M | 24.9M |
| Depreciation and amortization | 74.0M | 73.9M | 74.0M | 64.2M | 47.8M | 32.9M | 20.6M | 12.9M | 7.00M | 5.39M |
| EBITDA | 329.3M | 83.2M | 100.2M | -373.9M | -446.2M | -171.7M | -110.7M | 18.0M | 46.6M | 30.3M |
| Interest expense | 17.3M | 8.03M | 27.5M | 13.3M | 2.38M | 1.42M | 781.0K | 52.0K | 988.0K | 10.0K |
| Income before tax | -470.5M | -170.8M | 168.9M | -431.7M | -496.4M | -281.9M | -113.7M | 22.7M | 38.5M | 32.5M |
| Income tax | 61.9M | 2.98M | 6.01M | -3.72M | 4.58M | -477.0K | 3.83M | 1.94M | 11.5M | 5.97M |
| Net income | -532.8M | 2.96B | -95.5M | -226.9M | -347.9M | -204.9M | -96.9M | 21.2M | 26.1M | 26.2M |
| Earnings per share, basic | -0.24 | 1.36 | -0.05 | -0.11 | -0.17 | -0.10 | -0.05 | 0.01 | 0.02 | 0.02 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 173.6M | 132.0M | 1.45B | 1.02B | 1.18B | 629.1M | 252.4M | 494.6M | 123.9M | 136.5M |
| Short-term investments | 669.4M | 489.2M | 481.6M | 228.9M | 222.5M | 142.1M | 174.1M | 70.1M | 3.09M | 202.0K |
| Receivables | 133.9M | 118.7M | 218.8M | 104.3M | 142.4M | 165.7M | 87.6M | 67.8M | 255.4M | 20.0M |
| Inventory | 39.6M | 31.1M | 53.3M | 59.9M | 44.4M | 31.7M | 19.9M | 12.4M | 6.88M | 4.24M |
| Current assets | 1.06B | 835.0M | 2.35B | 1.76B | 1.64B | 993.2M | 554.0M | 679.5M | 397.9M | 163.9M |
| Property, plant and equipment | 646.9M | 499.0M | 379.2M | 265.6M | 158.0M | 80.5M | 43.7M | |||
| Goodwill | 1.37M | 1.34M | 1.36M | 2.55M | 14.2M | 14.1M | 15.2M | 15.3M | 1.47M | 1.38M |
| Total assets | 4.85B | 5.28B | 3.39B | 2.55B | 2.23B | 1.45B | 889.4M | 917.0M | 504.3M | 226.0M |
| Accounts payable | 36.8M | 29.8M | 40.0M | 55.8M | 30.2M | 23.4M | 17.6M | 11.2M | 8.15M | 4.35M |
| Current liabilities | 720.1M | 307.3M | 494.8M | 546.0M | 413.3M | 327.9M | 224.5M | 153.5M | 272.7M | 39.2M |
| Long-term debt | 0 | 17.3M | 287.2M | 261.0M | 121.1M | 1.26M | 1.75M | |||
| Total debt | 258.8M | 723.7M | 417.0M | 349.8M | 156.4M | 52.4M | 22.4M | 10.5M | ||
| Total liabilities | 876.3M | 954.9M | 1.34B | 1.18B | 846.2M | 631.8M | 517.1M | 423.7M | 275.9M | 42.0M |
| Shareholders' equity | 3.96B | 4.32B | 1.39B | 1.01B | 1.05B | 901.7M | 382.8M | 478.7M | 217.8M | 177.6M |
| Shares outstanding | 2.19B | 2.18B | 2.11B | 2.10B | 2.03B | 1.95B | 1.88B | 1.84B | 1.73B | 1.71B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 325.5M | 75.6M | -286.9M | -120.3M | -136.8M | -151.1M | -30.0M | 307.7M | 21.4M | 33.3M |
| Capital spending | -83.8M | -147.9M | -157.7M | -216.1M | -133.0M | -121.9M | -110.4M | -70.8M | -29.2M | -8.55M |
| Free cash flow | 241.7M | -72.3M | -444.6M | -336.4M | -269.8M | -273.0M | -140.3M | 236.8M | -7.85M | 24.7M |
| Cash from investing | -172.0M | -1.46B | -357.7M | -443.3M | -212.5M | -100.2M | -208.6M | -194.0M | -36.5M | -8.31M |
| Cash from financing | -144.9M | 66.5M | 1.07B | 419.3M | 902.1M | 624.2M | -2.78M | 257.3M | 2.04M | 8.49M |
| Dividends paid | 0 | -2.63M | -2.63M | |||||||
| Share buybacks | -225.1M | 13.5M | 1.03B | 423.3M | 951.2M | -9.46M | -7.77M | -11.5M | 2.94M | 11.3M |
| Change in cash | 10.5M | -1.31B | 422.4M | -157.0M | 551.9M | 376.7M | -242.2M | 370.7M | -12.6M | 32.7M |
Filings
All 14 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| PASSING AWAY OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES | Sep 16, 2026 | Management or board change | HKEX |
| INTERIM REPORT 2026 | Sep 16, 2026 | Interim report | HKEX |
| Next Day Disclosure Return | Sep 15, 2026 | Next day disclosure return | HKEX |
| COMPLETION OF PLACING OF NEW SHARES UNDER THE GENERAL MANDATE | Sep 15, 2026 | Financing | HKEX |
Cap table
Built by 6ix from GenScript Biotech Corporation’s releases
- Common shares
- 2,280,496,463
- Fully diluted
- 2,280,496,463
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,280,496,463 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,280,496,463 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Aixi Bai | General Manager of Bestzyme · Since at least Nov 5, 2026 |
| Allen Guo | CEO of ProBio · Since at least Nov 5, 2026 |
| Aylin Kosova Bilgin | Chief Marketing & Corporate Communications Officer · Since at least Jan 29, 2026 |
| Bhama Parimoo | Head of Global DEI · Since at least Nov 5, 2026 |
| Kate Grusich | Senior Corporate Communications Manager · Since at least Aug 18, 2026 |
| Kening Li | General Counsel and Chief Compliance Officer · Since at least Nov 5, 2026 |
| Martin Rexroad | General Manager of US Site for GenScript · Since at least Nov 5, 2026 |
| Phil Zhou | Chief Financial Officer of GenScript BioTech Corp. · Since at least Nov 5, 2026 |
| Ray Chen | President of GenScript Life Science Group · Since at least Jan 29, 2026 |
| Sherry Shao | Rotating CEO (on duty) of GenScript BioTech Corp. · Since at least Aug 18, 2026 |
Log in to ask 6ix AI your own questions about GenScript Biotech Corporation.